This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Invest in Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Hill-Rom's (HRC) M&A pipeline continues to be strong.
Boston Scientific (BSX) to Buy Residual Shares of Millipede
by Zacks Equity Research
Boston Scientific's (BSX) buyout of the leftover stake in Millipede will integrate the latter's IRIS Transcatheter Annuloplasty Ring System in the Structural Heart portfolio of the former.
Zimmer Biomet (ZBH) Thrives on New Projects, APAC Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) is performing well on the back of its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application.
Why Is Veeva (VEEV) Down 11.3% Since Last Earnings Report?
by Zacks Equity Research
Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ecolab Inks Deal With Clearway for Renewable Power Project
by Zacks Equity Research
Ecolab's (ECL) virtual power purchase agreement with Clearway is part of a broader trend among corporate buyers. This will cover the company???s annual domestic energy use completely.
Here's Why Investors Should Retain CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED's (CNMD) steady focus on innovation is indicative of brighter prospects ahead. The company faces cutthroat competition in the niche space.
Becton, Dickinson's MAX Enteric Viral Panel Cleared by FDA
by Zacks Equity Research
Becton, Dickinson's (BDX) Diagnostic Systems portfolio lends it a competitive edge.
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
by Zacks Equity Research
A solid outlook for 2018 and strength in robotics make Intuitive Surgical (ISRG) a promising investment pick.
Medtronic's Growth Across All Lines Aid, Rising Costs Ail
by Zacks Equity Research
Of late, Medtronic (MDT) succeeds in delivering solid top-line growth at CER, backed by balanced growth across major business operation.
Myriad Genetics Posts Positive Adjusted Vectra Test Data
by Zacks Equity Research
The key finding of Myriad Genetics' (MYGN) study proves that the adjusted Vectra score beats all traditional measures of disease activity to predict radiographic progression in RA patients.
SYK vs. SRDX: Which MedTech Stock Should Investors Pick?
by Zacks Equity Research
Surmodics (SRDX) scores higher than Stryker (SYK) in terms of current-year revenue projections and fundamentals.
Varian Medical's (VAR) Halcyon Excluded From Trade Tariffs
by Zacks Equity Research
Recent trade war-related talks are likely to favor Varian Medical (VAR) in the long run.
Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now
by Zacks Equity Research
Plethora of developments for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.
Here's Why You Should Buy Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
As a result of continued efforts to streamline operations, Integer Holdings (ITGR) has been registering strong profits over the last couple of quarters.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now expanding considerably in the international arena.
Is Veeva Systems (VEEV) Outperforming Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?
Integra Rides on Global Prospects, Hurt by Escalating Costs
by Zacks Equity Research
Integra LifeSciences (IART) aims at investment openings in the Asian market for a faster business boost than in the United States and also to flourish specific parts of its international businesses.
Quest Diagnostics (DGX) Divests India Business to Strand
by Zacks Equity Research
Quest Diagnostics (DGX) sees lucrative prospects in the U.S. diagnostic testing market.
Hill-Rom Grows on Acquisitions, Asia Pacific Sales Drop
by Zacks Equity Research
Hill-Rom (HRC) is actively pursuing buyouts to accelerate growth across five key clinical areas.
Cala Health Picks Medidata Cloud for Observational Study
by Zacks Equity Research
Medidata's (MDSO) Cloud platform sees a slew of developments in recent times.
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to gain from its Mako robotics platform, which has been the key driver of the company's core Orthopaedic segment.
Is Veeva Systems (VEEV) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Veeva Systems (VEEV).
Walgreens (WBA) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens' (WBA) retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market.
Walgreens-Alphabet Join Forces to Control Healthcare Costs
by Zacks Equity Research
Walgreens (WBA) and Alphabet's arm Verily to start a medication adherence pilot project that will deploy equipment and other methods to improve adherence.
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
by Zacks Equity Research
Myriad Genetics (MYGN) progresses well with initiatives to boost the uptake of the BRACAnalysis CDx test. The recent approval to increase the customer base is an added positive.